1 asive assessment of transmural and selective
endomyocardial and epimyocardial perfusion.
2 Endomyocardial and skeletal muscle biopsies from affecte
3 patients who were monitored with the use of
endomyocardial biopsies (0.5 vs. 3.0, P<0.001).
4 Endomyocardial biopsies (EMB) from heart failure (HF) pa
5 -CD68) and histopathologic criteria found on
endomyocardial biopsies (EMB).
6 on after heart transplant (HT), surveillance
endomyocardial biopsies (EMBs) are often continued for y
7 To determine the utility of surveillance
endomyocardial biopsies (EMBs) during a 14-day OKT3 indu
8 e total Treg population, we examined Treg in
endomyocardial biopsies (EMBs) of both patients who deve
9 d for the presence of viral genome in serial
endomyocardial biopsies (EMBs) using polymerase chain re
10 ng (EVM) is a promising modality for guiding
endomyocardial biopsies (EMBs).
11 ited utilization and the poor sensitivity of
endomyocardial biopsies (especially for patchy diseases
12 Percentage of
endomyocardial biopsies (grade 3a, 3b, and 4) with respe
13 ig), and their receptor CXCR3 in consecutive
endomyocardial biopsies (n = 133) from human cardiac all
14 Antigen expression was detected on
endomyocardial biopsies (n = 50) and spleen (n = 11) by
15 ion of VEGF by immunohistochemistry in human
endomyocardial biopsies (n=101) from 10 cardiac transpla
16 We obtained left ventricular
endomyocardial biopsies (n=12) for mRNA expression analy
17 ood mononuclear cells (n=24), plasma (n=27),
endomyocardial biopsies (n=2), and cardiac tissue sample
18 ation relies on histopathological grading of
endomyocardial biopsies according to International Socie
19 Endomyocardial biopsies and blood samples from 38 patien
20 METHODS AND
Endomyocardial biopsies and blood samples were obtained
21 We reviewed the simultaneously obtained
endomyocardial biopsies and intravascular ultrasound (IV
22 We evaluated PIMI in the first four weekly
endomyocardial biopsies and/or autopsy myocardium from 1
23 Repeat
endomyocardial biopsies are frequently needed to diagnos
24 the major limitations, and currently, serial
endomyocardial biopsies are required to diagnose rejecti
25 VEGF is expressed in normal human
endomyocardial biopsies at low levels and is induced (sc
26 of patients with DCM, 99 patients underwent
endomyocardial biopsies before CRT implantation, with hi
27 We analyzed 169 sequential human
endomyocardial biopsies by immunocytochemistry for infil
28 were also found to be clonally explanted in
endomyocardial biopsies collected 17 and 21 mo earlier f
29 cular atheroma excised at endarterectomy and
endomyocardial biopsies contained purely variant fibrino
30 schemic changes in early posttransplantation
endomyocardial biopsies correlate with the later develop
31 GF) mRNA expression was determined in serial
endomyocardial biopsies during the first year after tran
32 Endomyocardial biopsies fibrosis did not relate to CRT r
33 Endomyocardial biopsies from 19 old patients with a dila
34 ir receptors CXCR3 and CCR5 was tested in 60
endomyocardial biopsies from 24 patients using quantitat
35 Right ventricular
endomyocardial biopsies from 30 cases of allograft rejec
36 ern of vascular cardiac allograft rejection,
endomyocardial biopsies from 344 heart transplant recipi
37 D We analyzed pretreatment and posttreatment
endomyocardial biopsies from 58 Fabry patients enrolled
38 Autopsy specimens from 5 patients and
endomyocardial biopsies from 7 patients were used for th
39 estigated in both cultured keratinocytes and
endomyocardial biopsies from affected individuals.
40 the presence of acute cellular rejection in
endomyocardial biopsies from cardiac transplant recipien
41 ve RT-PCR in RNA from right ventricular (RV)
endomyocardial biopsies from intact nonfailing hearts, a
42 properties of mCSCs and vCSCs isolated from
endomyocardial biopsies from patients with advanced hear
43 d (P=0.012) and 5.1-fold (P=0.038) higher in
endomyocardial biopsies from patients with CVB3-positive
44 ntiated adult heart muscle cells, studies in
endomyocardial biopsies from patients with dilated and i
45 luorescence, and immunoperoxidase studies of
endomyocardial biopsies from such patients often reveal
46 erum samples were retrospectively matched to
endomyocardial biopsies in 98 cardiac transplant recipie
47 Protocol
endomyocardial biopsies in all three patients revealed n
48 Endomyocardial biopsies in those with elevated AT1R-Ab l
49 n-fixed, paraffin-embedded right ventricular
endomyocardial biopsies is diagnostic of immunopathologi
50 +) T cells and the CXCR3 ligand IP-10 within
endomyocardial biopsies is strongly associated with acut
51 in pathologic processes, Egr-1 expression in
endomyocardial biopsies may act as a surrogate marker of
52 ry deposition of C4d or C3d were detected in
endomyocardial biopsies of 14 of the 33 patients.
53 observed an increase in MYOCD levels in the
endomyocardial biopsies of DCM patients associated with
54 Egr-1 protein expression was analyzed in
endomyocardial biopsies of different rejection grades by
55 PAR2 expression in
endomyocardial biopsies of patients with nonischemic car
56 myocardial fibrosis has been detected in the
endomyocardial biopsies of survivors.
57 ling of protein-coding genes and 754 miRs in
endomyocardial biopsies of test cohorts was performed at
58 We performed
endomyocardial biopsies of the RV side of the septum and
59 ology and sarcomere alterations described in
endomyocardial biopsies of transplant patients with reje
60 d RNA sequencing on right ventricular septal
endomyocardial biopsies prospectively obtained from pati
61 ere-derived cells (CDCs) isolated from human
endomyocardial biopsies reduce infarct size and improve
62 Analysis of serial
endomyocardial biopsies revealed that high levels of end
63 Cardiac transcriptomic profiling of
endomyocardial biopsies reveals a strong proinflammatory
64 A total of 240 heart transplant
endomyocardial biopsies were assessed.
65 To determine whether ischemic changes in
endomyocardial biopsies were associated with complement
66 A total of 132 blood specimens and
endomyocardial biopsies were collected from 35 patients,
67 Endomyocardial biopsies were collected with a bioptome f
68 Serial
endomyocardial biopsies were evaluated for cellular reje
69 Endomyocardial biopsies were evaluated within 2 weeks of
70 Porcine
endomyocardial biopsies were harvested and plated as org
71 Autologous cardiospheres or CDCs grown from
endomyocardial biopsies were injected through thoracotom
72 gery (mean follow-up 8.3 months) when repeat
endomyocardial biopsies were obtained to correlate trans
73 Serial radionuclide ventriculography and
endomyocardial biopsies were performed at baseline, 3, a
74 tegory (1R) appears to have brought together
endomyocardial biopsies with different underlying proces
75 eactivity was not detectable in four of five
endomyocardial biopsies with normal histology.
76 with histologically proven amyloid (374 with
endomyocardial biopsies) and 360 patients subsequently c
77 oronary computed tomography angiography, and
endomyocardial biopsies).
78 ranscriptional profiling was performed on 26
endomyocardial biopsies, and expression patterns were co
79 thy-associated gene-panel, echocardiography,
endomyocardial biopsies, and Holter monitoring.
80 Annual coronary angiograms, serial
endomyocardial biopsies, and serum cardiac troponin-T co
81 ression profiling or with the use of routine
endomyocardial biopsies, in addition to clinical and ech
82 Serial cardiac monitoring, including
endomyocardial biopsies, was performed.
83 onresponse to CRT in patients with DCM using
endomyocardial biopsies.
84 in human atrial tissue and right ventricular
endomyocardial biopsies.
85 Egr-1 mRNA expression and rejection grade in
endomyocardial biopsies.
86 men was used, and rejection was monitored by
endomyocardial biopsies.
87 nd arteriolar endothelial ICAM-1 in matching
endomyocardial biopsies.
88 were measured in 186 patients undergoing 365
endomyocardial biopsies.
89 187 adult HTx patients with contemporaneous
endomyocardial biopsies.
90 not predominantly lymphocytic myocarditis in
endomyocardial biopsies.
91 ents could obviate the need for surveillance
endomyocardial biopsies.
92 of ATTR-CM without the need for confirmatory
endomyocardial biopsies; observational studies indicate
93 Each sample was paired with an
endomyocardial biopsy (<30 days).
94 After a low-grade
endomyocardial biopsy (0 or 1A), one or more donor-recip
95 9%) had history of myocarditis diagnosed by
endomyocardial biopsy (59%) and/or cardiac magnetic reso
96 pathology were addressed: (a) Improvement of
endomyocardial biopsy (EMB) accuracy for the diagnosis o
97 Endomyocardial biopsy (EMB) has a low sensitivity.
98 Endomyocardial biopsy (EMB) has an important role in det
99 diac magnetic resonance (CMR) mapping versus
endomyocardial biopsy (EMB) has not been determined.
100 ration and frequency of routine surveillance
endomyocardial biopsy (EMB) have been questioned in the
101 d many to question the yield of surveillance
endomyocardial biopsy (EMB) in heart transplantation (HT
102 Endomyocardial biopsy (EMB) is a low risk procedure in a
103 The
endomyocardial biopsy (EMB) is considered the gold stand
104 Endomyocardial biopsy (EMB) is often considered when the
105 ac transplantation, and regular surveillance
endomyocardial biopsy (EMB) is required.
106 Endomyocardial biopsy (EMB) is the gold standard method
107 ue of the distinction between CS and IGCM on
endomyocardial biopsy (EMB) is unknown.
108 tic resonance (CMR), cardiac biomarkers, and
endomyocardial biopsy (EMB) results to predict left vent
109 Endomyocardial biopsy (EMB) screening represents the sta
110 Use of left ventricular (LV)
endomyocardial biopsy (EMB) to investigate cardiomyopath
111 tients who had blood samples obtained during
endomyocardial biopsy (EMB).
112 e evidence of antibody-mediated rejection by
endomyocardial biopsy (EMB).
113 After heart transplantation,
endomyocardial biopsy (EMBx) is used to monitor for acut
114 uring subsequent cardiac surgery (n = 3) and
endomyocardial biopsy (n = 1).
115 (n = 26), coronary angiography (n = 32), and
endomyocardial biopsy (n = 32).
116 rdiac tissues obtained from autopsies (n=3),
endomyocardial biopsy (n=1), or cardiac transplants (n=2
117 rol had antibody-mediated rejection (AMR) by
endomyocardial biopsy (P<0.01).
118 There was a decrease in the use of
endomyocardial biopsy (P=0.03) and an increase in the us
119 y correlated with inflammatory cell count on
endomyocardial biopsy (r=0.56; P<0.05).
120 AM and PM groups were defined based on
endomyocardial biopsy and cardiac magnetic resonance fin
121 retrospectively identified who had undergone
endomyocardial biopsy and cardiac MR at one institution
122 d clinically suspected myocarditis underwent
endomyocardial biopsy and CMR at 1.5 Tesla.
123 Acute allograft rejection was diagnosed by
endomyocardial biopsy and graded according to the Intern
124 disorder has led to the possible overuse of
endomyocardial biopsy and immunosuppressive agents.
125 transplant recipients underwent simultaneous
endomyocardial biopsy and intravascular ultrasound (IVUS
126 nts require more invasive procedures such as
endomyocardial biopsy and may aid in reducing the number
127 ave myocarditis according to the findings on
endomyocardial biopsy and the Dallas histopathological c
128 Rejection was diagnosed using
endomyocardial biopsy and were graded according to stand
129 ant recipients who were referred for routine
endomyocardial biopsy and/or surveillance coronary angio
130 Cardiac magnetic resonance imaging or
endomyocardial biopsy are required for definitive diagno
131 itivity or specificity needed to replace the
endomyocardial biopsy as a diagnostic tool.
132 jection in humans might obviate the need for
endomyocardial biopsy as well as improve the accuracy of
133 including TD imaging, along with transmural
endomyocardial biopsy at the time of coronary bypass sur
134 sis of 196 consecutive patients referred for
endomyocardial biopsy because of clinical suspicion of c
135 All underwent an
endomyocardial biopsy before randomization, which reveal
136 Endomyocardial biopsy can demonstrate fibro-fatty replac
137 In some patients, cardiac MRI and
endomyocardial biopsy can help identify myocarditis, pre
138 that transcriptomic biomarkers from a single
endomyocardial biopsy can improve the clinical detection
139 nological factors at the time of a low-grade
endomyocardial biopsy can predict progression to high-gr
140 Among 74 patients with
endomyocardial biopsy diagnosis of FD cardiomyopathy, 13
141 transplant recipients following inadvertent
endomyocardial biopsy disruption of the tricuspid appara
142 nological factors at the time of a low-grade
endomyocardial biopsy enables prospective stratification
143 Endomyocardial biopsy fibrosis was quantitatively measur
144 ional research that influence the utility of
endomyocardial biopsy for the management of inflammatory
145 Endomyocardial biopsy has defined rejection in clinical
146 The
endomyocardial biopsy has defined the diagnosis of rejec
147 The
endomyocardial biopsy has long been the preferred techni
148 res surrogate cardiac imaging biomarkers, as
endomyocardial biopsy has relatively low yield, even wit
149 Endomyocardial biopsy has stood the test of time as a su
150 nce of significant rejection on the basis of
endomyocardial biopsy histology.
151 Findings were confirmed by
endomyocardial biopsy in 64% (29 of 45) of participants.
152 he diagnosis, partly due to the low yield of
endomyocardial biopsy in cardiac sarcoidosis.
153 ed recently as potential substitutes for the
endomyocardial biopsy in detecting rejection.
154 nvasive test holds promise for replacing the
endomyocardial biopsy in heart transplant recipients and
155 9 (terminal pathway), at the time of routine
endomyocardial biopsy in heart transplant recipients.
156 uptake on bone scintigraphy and/or positive
endomyocardial biopsy in the absence of monoclonal prote
157 This article reviews the current role of the
endomyocardial biopsy in the management of patients foll
158 The sensitivity of transvenous
endomyocardial biopsy increased from 68% (19/28 patients
159 e DNA from the donor genome at times when an
endomyocardial biopsy independently established the pres
160 Percutaneous
endomyocardial biopsy is a widely used and valuable proc
161 The
endomyocardial biopsy is also limited by sub-optimal int
162 Endomyocardial biopsy is confirmatory for myocarditis, b
163 Endomyocardial biopsy is currently the standard method u
164 Risk of
endomyocardial biopsy is highest in sick children with s
165 gnostic yield of cardiac sarcoidosis (CS) by
endomyocardial biopsy is limited.
166 are often used as initial diagnostic tests,
endomyocardial biopsy is required for definitive diagnos
167 Although
endomyocardial biopsy is the criterion standard diagnost
168 Endomyocardial biopsy is the major method for detecting
169 Endomyocardial biopsy is the standard method of monitori
170 Endomyocardial biopsy is used routinely for diagnosing a
171 The sensitivity of
endomyocardial biopsy may be increased, especially in su
172 rranted to characterize patients with TCM by
endomyocardial biopsy more clearly.
173 METHODS AND
Endomyocardial biopsy NOD2 mRNA expression was higher in
174 Endomyocardial biopsy on postoperative day 56 showed fib
175 Nine episodes of CAVB occurred during
endomyocardial biopsy or coronary angiography, and four
176 Results were correlated with
endomyocardial biopsy rejection grades.
177 Cardiac catheterization and
endomyocardial biopsy remain the "gold standard" for dia
178 Endomyocardial biopsy remains the gold standard for in v
179 ith cardiac biomarkers, cardiac imaging, and
endomyocardial biopsy represent a pragmatic diagnostic a
180 etection of transplant rejection by repeated
endomyocardial biopsy requires catheterization and entai
181 fraction to < or = 40%, and one because her
endomyocardial biopsy result was grade 1.5.
182 The therapeutic and prognostic benefits of
endomyocardial biopsy results have recently been demonst
183 Endomyocardial biopsy revealed active myocarditis in 16
184 At postoperative day 50, the
endomyocardial biopsy revealed damaged capillaries with
185 Endomyocardial biopsy revealed more advanced grade C and
186 mmunological and histological analyses of an
endomyocardial biopsy sample are indicated when inflamma
187 in patients with new-onset HF from a single
endomyocardial biopsy sample.
188 , 101b, 21a) were compared with time-matched
endomyocardial biopsy samples (n = 70) in 12 patients to
189 Endomyocardial biopsy samples and clinical data were col
190 The current study investigated
endomyocardial biopsy samples from patients with TCM and
191 Levels of TSP-1 mRNA in
endomyocardial biopsy samples of human cardiac allograft
192 Immunohistochemistry of
endomyocardial biopsy samples revealed altered expressio
193 entification of infiltration and fibrosis in
endomyocardial biopsy samples to assess transplant rejec
194 In cases of myocarditis (n=7),
endomyocardial biopsy samples were analyzed by PCR and c
195 Serial LV
endomyocardial biopsy samples were obtained at each echo
196 Serial LV
endomyocardial biopsy samples were obtained to measure c
197 Matching
endomyocardial biopsy samples were screened immunohistoc
198 Among a total of 350
endomyocardial biopsy samples, 180 were identified as id
199 nd arterial endothelial ICAM-1 expression in
endomyocardial biopsy samples.
200 ulation of SA CMCs was isolated from porcine
endomyocardial biopsy samples.
201 F) were correlated with clinical outcome and
endomyocardial biopsy scores.
202 diac fibrosis was assessed histologically on
endomyocardial biopsy sections.
203 Endomyocardial biopsy should be broadly and promptly use
204 and electroanatomical voltage mapping-guided
endomyocardial biopsy showed low endocardial voltages an
205 Endomyocardial biopsy showed mononuclear infiltrates and
206 c right ventricular cardiomyopathy and of an
endomyocardial biopsy showing fibro-fatty replacement co
207 lar rejection grading scheme for heart graft
endomyocardial biopsy specimens (EMBs).
208 Standard morphological features of
endomyocardial biopsy specimens do not necessarily corre
209 A total of 157
endomyocardial biopsy specimens from 26 patients with he
210 Three hundred sixteen serial
endomyocardial biopsy specimens from 30 heart transplant
211 Endomyocardial biopsy specimens from 40 patients with pr
212 We studied
endomyocardial biopsy specimens from 7 sex-mismatched (f
213 as is expressed on myocytes, we investigated
endomyocardial biopsy specimens from cardiac transplant
214 okine and receptor gene expression in serial
endomyocardial biopsy specimens from heart transplant pa
215 e-transcriptase polymerase chain reaction in
endomyocardial biopsy specimens from human heart transpl
216 Serial sections of individual
endomyocardial biopsy specimens from patients histologic
217 Percutaneous
endomyocardial biopsy specimens grown in primary culture
218 In addition, studies of
endomyocardial biopsy specimens have furthered our under
219 d percent fibrosis were determined in serial
endomyocardial biopsy specimens obtained from 1 month up
220 Immunocytochemistry was performed on serial
endomyocardial biopsy specimens to evaluate endothelial
221 Endomyocardial biopsy specimens were evaluated during th
222 to receive CDCs, autologous cells grown from
endomyocardial biopsy specimens were infused into the in
223 ologous CDCs (12.5 to 25 x 10(6)) grown from
endomyocardial biopsy specimens were infused via the int
224 B19V DNA and messenger RNA from
endomyocardial biopsy specimens, bone marrow specimens,
225 the isolation of adult human stem cells from
endomyocardial biopsy specimens.
226 expression was increased during rejection in
endomyocardial biopsy specimens.
227 +/- standard deviation) consecutive routine
endomyocardial biopsy surveillance visits during the fir
228 ications, the authors do not advocate use of
endomyocardial biopsy to diagnose myocarditis in the set
229 Endomyocardial biopsy was conducted in 5 patients and re
230 including patients with ATTR-CA diagnosed by
endomyocardial biopsy was conducted.
231 Gal-3 levels and inflammatory cell count on
endomyocardial biopsy was observed in patients with iCMP
232 m each patient were examined for AECA and an
endomyocardial biopsy was performed at regular intervals
233 Endomyocardial biopsy was performed in 9 of the 12 ARVD/
234 Endomyocardial biopsy was safe, and cardiac magnetic res
235 methods for the detection of rejection, the
endomyocardial biopsy will remain important in the manag
236 inical safety of any such approach, invasive
endomyocardial biopsy will remain the gold standard.
237 ized that the transcriptome obtained from an
endomyocardial biopsy would yield clinically relevant an
238 hs, 64% occurred within 3 months of the last
endomyocardial biopsy, 96% had normal biopsies, and the
239 ter nucleic acids had been extracted from an
endomyocardial biopsy, an explant, or autopsy samples, P
240 echocardiogram, right ventricular angiogram,
endomyocardial biopsy, and 24-hour ambulatory ECG.
241 criptomic signature, generated from a single
endomyocardial biopsy, could serve as a novel prognostic
242 Myocardial tissue from
endomyocardial biopsy, explant, or autopsy was analyzed
243 ve addressed important issues concerning the
endomyocardial biopsy, including the reliability of the
244 n the invasive and low-sensitivity nature of
endomyocardial biopsy, its diagnostic focus shifted to a
245 Endomyocardial biopsy, lymphocyte-growth assays, and ant
246 Endomyocardial biopsy, mainly right ventricular, had a s
247 ere positive, concomitantly with a low-grade
endomyocardial biopsy, the positive predictive value for
248 ionship between MDR1/ABCB1 polymorphisms and
endomyocardial biopsy-proven rejection (EBPR) determined
249 cally, the diagnosis of myocarditis required
endomyocardial biopsy.
250 en shown to correlate with the results of an
endomyocardial biopsy.
251 the standard method of tissue histology from
endomyocardial biopsy.
252 Nine patients underwent
endomyocardial biopsy.
253 and serial echocardiography; five underwent
endomyocardial biopsy.
254 gs in the diagnosis of amyloidosis proven by
endomyocardial biopsy.
255 assessed by the rejection grade on the first
endomyocardial biopsy.
256 osis on the basis of clinical evaluation and
endomyocardial biopsy.
257 of MMF trough level at the time of scheduled
endomyocardial biopsy.
258 c transplants revolves around the use of the
endomyocardial biopsy.
259 DSE at the time of their regularly scheduled
endomyocardial biopsy.
260 lantation at the time of serial surveillance
endomyocardial biopsy.
261 uded, of whom 142 underwent TTE before first
endomyocardial biopsy.
262 asive coronary angiography, cardiac MRI, and
endomyocardial biopsy.
263 nical signs and symptoms and low accuracy of
endomyocardial biopsy.
264 ransplantation (ISHLT) grade 2R or higher at
endomyocardial biopsy.
265 ic work-up, including genetic evaluation and
endomyocardial biopsy.
266 ditis was defined by ongoing inflammation on
endomyocardial biopsy.
267 Twenty-eight (88%) patients underwent
endomyocardial biopsy.
268 ars) had undergone diagnostic cardiac MR and
endomyocardial biopsy.
269 mic myocardial (18)F-NOS PET/CT, followed by
endomyocardial biopsy.
270 nd immunoglobulins) and microvasculopathy in
endomyocardial biopsy.
271 For
endomyocardial-
biopsy grades 1B or 2, a positive lymphoc
272 munohistochemical analysis of a conventional
endomyocardial-
biopsy sample appears to be a highly sens
273 Endomyocardial-
biopsy specimens were evaluated for evide
274 echocardiograms, hemodynamic parameters, and
endomyocardial biopsys from 137 patients with heart tran
275 XFM using external fiducial markers to guide
endomyocardial cell injections in infarcted swine hearts
276 e rise to an inflammatory process leading to
endomyocardial damage and scar formation.
277 Percutaneous
endomyocardial drug delivery is feasible with the aid of
278 ocardial perfusion reserve (MPR) and resting
endomyocardial/
epimyocardial perfusion ratio (Endo/Epi r
279 Tropical
endomyocardial fibrosis (EMF) is a neglected disease of
280 Two patients with
endomyocardial fibrosis were maintained on imatinib 300
281 Endomyocardial fibrosis, first described >75 years ago,
282 tes and the quality of life of patients with
endomyocardial fibrosis.
283 ncentrations of Gal-3 do not seem to reflect
endomyocardial Gal-3 levels or cardiac fibrosis.
284 evaluate the outcome and prevalence of viral
endomyocardial infection after cardiac transplantation.
285 Viral
endomyocardial infection is an independent predictor of
286 howed <5% apoptotic mononuclear cells in the
endomyocardial infiltrates.
287 ophysiologic mechanisms include systemic and
endomyocardial inflammation with fibrosis.
288 external fiducial markers accurately targets
endomyocardial injection in a swine model of myocardial
289 ed to receive 5, 15, or 30 mg of JVS-100 via
endomyocardial injection.
290 od Manufacturing Practice, were delivered by
endomyocardial injections guided by left ventricular ele
291 Endomyocardial injections of iron-labeled mesenchymal st
292 More than 50
endomyocardial injections were performed with the aid of
293 regional denervation 3 d after placement of
endomyocardial laser channels.
294 but not pravastatin, decreased the degree of
endomyocardial mononuclear cell infiltration seen with R
295 Twenty-six patients (81%) were diagnosed by
endomyocardial or surgical biopsies and 6 at autopsy or
296 Conventional
endomyocardial samples contain morphological information
297 Delivery and tracking of
endomyocardial stem cells are limited by the inability t
298 Endomyocardial tissue and peripheral blood mononuclear c
299 ) infection was identified during testing of
endomyocardial tissue from the heart recipient.
300 y be able to improve the diagnostic yield of
endomyocardial ventricular biopsy.